ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2017 American Transplant Congress

    Different Prognostic Factors for Early and Late Recurrence After Adult Living Donor Liver Transplantation for Hepatocellular Carcinoma.

    S. Hong, K.-W. Lee, H.-S. Kim, S.-W. Ahn, K. Yoon, H. Kim, N.-J. Yi, K.-S. Suh.

    Surgery, College of Medicine, Seoul National University, Seoul, Republic of Korea

    Recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains unsatisfactory. However, some patients with HCC recurrence after LT show good long-term survival results. The…
  • 2017 American Transplant Congress

    Effects of the Gut-Liver Axis on Ischemia-Mediated Hepatocellular Carcinoma Recurrence in the Mouse Liver.

    L. Orci,1 S. Lacotte,1 V. Delaune,1 G. Oldani,1 F. Slits,1 C. Rossetti,2 L. Rubbia-Brandt,3 P. Morel,1 C. Toso.1

    1Hepato-pancreato-biliary Centre, Department of Surgery, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; 2Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell'Insubria, Varese, Italy; 3Division of Clinical Pathology, Department of Pathology and Immunology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

    Background: There is growing evidence that liver graft ischemia-reperfusion (I/R) is a risk factor for hepatocellular carcinoma (HCC) recurrence after liver transplantation, but the involved…
  • 2017 American Transplant Congress

    The Glasgow Prognostic Score and Its Variants Predict Mortality in Living Donor but Not in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: A Double-Center Validation Study.

    A. Kaltenborn,1 J. Gwiasda,1 N. Heits,2 F. Braun,2 H. Schrem.1

    1Core Facility Quality Management Transplantation, Hannover Medical School, Hannover, Germany; 2Department of General, Visceral-, Thoracic-, Transplantation- and Pediatric Surgery, University Medical Center Schleswig-Holstein, Kiel, Germany

    The notion that inflammation parameters such as CRP and albumin might have an influence on outcome in malignant disease is gaining interest. Serum CRP- and…
  • 2017 American Transplant Congress

    The Beneficial Effects of mTOR Inhibitors on Liver Resident Natural Killer Cells.

    J. Saparbay, Y. Tanaka, T. Yano, H. Ohdan.

    Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan

    (Background) The immunosuppressive regimen currently used after organ transplantation reduces adaptive components. Therefore, the innate immune cells play pivotal roles in immune surveillance and defense…
  • 2017 American Transplant Congress

    Incidental Hepatocellular Carcinoma in Explanted Livers: An Assessment After LIRADS Introduction.

    S. Garcia Aroz,1 D. Ludwig,2 K. Fowler,2 N. Vachharajani,1 M. Xu,1 Y. Lin,1 M. Doyle,1 W. Chapman.1

    1Surgery, Washington University, St. Louis, MO; 2Radiology, Washington University, St. Louis, MO

    Background: Despite new technologies and improvements in imaging diagnosis, incidental and misdiagnosed hepatocellular carcinomas (HCC) are entities that remain present and problematic in liver transplantation.Methods:…
  • 2017 American Transplant Congress

    Proposal for HCC Exception Points to Match Drop Out Risk.

    H. Yeh,3 M. Akan,1 N.-H. Leung,2 J. Markmann,3 S. Tayur.1

    1CMU, Pittsburgh; 2City U, Hong Kong, Hong Kong; 3MGH, Boston

    Background: Recent changes in HCC exception point policy aims to equalize wait list outcomes between HCC and non-HCC patients, but remains dissociated from tumor biology.…
  • 2017 American Transplant Congress

    A New Strategy for Loco-Regional Therapy of Hepatocellular Carcinoma: Stereotactic Body Radiotherapy as a Bridge to Liver Transplantation.

    T. Uemura,1 A. Kirichenko,2 M. Bunker,3 M. Vincent,1 L. Machado,1 A. Singhal,1 N. Thai.1

    1Transplant Surgery, Allegheny General Hospital, Pittsburgh; 2Radiation Oncology, Allegheny General Hospital, Pittsburgh; 3Pathology, Allegheny General Hospital, Pittsburgh

    Background: Transarterial chemoembolization (TACE) or radiofrequency ablation are often used as local Hepatocellular Carcinoma (HCC) treatment while waiting for a liver transplant (LTx). However, it…
  • 2017 American Transplant Congress

    Exception Scores for Patients on the Liver Waiting List.

    T. Weaver,1 D. Schladt,1 M. Skeans,1 J. Pyke,1 J. Zeglin,1 S. Leppke,1 A. Israni,1,2 B. Kasiske,1,2 W. Kim,3 J. Lake.4

    1Scientific Registry of Transplant Recipients, Minneapolis, MN; 2Hennepin County Medical Center, Minneapolis, MN; 3Stanford University, Stanford, CA; 4University of Minnesota, Minneapolis, MN

    Liver waitlist candidates are prioritized for allocation using model for end-stage liver disease (MELD) scores, and some patients receive higher MELD scores through exception. The…
  • 2017 American Transplant Congress

    Recurrent HCC After Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation.

    H. Muaddi,1 D. Al-Adra,1 J. Shaw,1 D. Grant,1 P. Greig,1 I. McGilvray,1 M. Cattral,1 A. Wei,1 C.-A. Moulton,1 J. Kachura,2 R. Beecroft,2 M. Selzner,1 A. Ghanekar,1 S. Gallinger,1 S. Cleary,1 G. Sapisochin.1

    1General Surgery, University of Toronto, Toronto, ON, Canada; 2Medical Imaging, University of Toronto, Toronto, ON, Canada

    Background:Liver resection (LR) and radiofrequency ablation (RFA) represent curative therapies for early stages of hepatocellular carcinoma (HCC). If tumour recurrence occurs, salvage liver transplant (SLT)…
  • 2017 American Transplant Congress

    HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.

    J. Emamaullee, M. Bral, G. Meeberg, A. Montano-Loza, V. Bain, D. Bigam, N. Kneteman, A. Shapiro.

    University of Alberta, Edmonton, AB, Canada

    Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences